Kodiak Sciences Inc   (KOD)
Other Ticker:  
Price: $6.0100 $0.00 0.000%
Day's High: $6.26 Week Perf: 0.84 %
Day's Low: $ 5.92 30 Day Perf: 49.88 %
Volume (M): 509 52 Wk High: $ 9.80
Volume (M$): $ 3,061 52 Wk Avg: $4.15
Open: $6.03 52 Wk Low: $1.37

 Market Capitalization (Millions $) 315
 Shares Outstanding (Millions) 52
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -271
 Cash Flow (TTM) (Millions $) 167
 Capital Exp. (TTM) (Millions $) 17

Kodiak Sciences Inc
Kodiak Sciences Inc. is a biopharmaceutical company that focuses on the development of novel therapies for the treatment of retinal diseases. The company's main area of expertise is in ocular medicine, particularly in targeting and treating chronic conditions that affect the retina.

Kodiak Sciences has developed a proprietary platform technology called the Antibody Biopolymer Conjugate (ABC) platform, which allows for the design and development of potent and durable medicines. By combining the benefits of biologics with the advantages of small molecules, the company aims to deliver innovative therapies that can significantly improve patient outcomes.

One of Kodiak Sciences' most promising drug candidates is KSI-301, a potential treatment for wet age-related macular degeneration (AMD) and diabetic macular edema (DME). KSI-301 has shown promising results in clinical trials, demonstrating its potential to provide improved efficacy and longer duration of action compared to current standard-of-care therapies.

Overall, Kodiak Sciences Inc. is a research-driven biopharmaceutical company that is dedicated to developing transformative treatments for retinal diseases, ultimately aiming to improve the lives of patients suffering from severe and debilitating eye conditions.

   Company Address: 1200 Page Mill Road Palo Alto 94304 CA
   Company Phone Number: 281-0850   Stock Exchange / Ticker: NASDAQ KOD
   KOD is expected to report next financial results on March 27, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Kodiak Sciences Inc

Kodiak Sciences Inc Shows Significant Improvement with $-54.5 Million Operating Loss in Q3 2023

Despite trailing behind major players in the Biotechnology & Pharmaceuticals industry, smaller entities like Kodiak Sciences Inc (KOD) are making substantial progress in terms of their financial performance. KOD recently announced its operating loss of $-54.5 million for the third quarter of 2023, displaying a significant improvement compared to the operating loss of $-79.478 million in the same period last year. This positive development highlights the company's determination to enhance its business model and achieve sustainable growth.
Efficient Management and Steady Progress
In an era where rising businesses like KOD need to operate efficiently to reach the next level, the management of Kodiak Sciences Inc has executed strategies to run the company more effectively during the fiscal time-frame ending September 30, 2023. The reduction of the deficit to $-50.007 million demonstrates the management's commitment to streamlining operations and controlling costs.

Kodiak Sciences Inc

Kodiak Sciences Inc Surprises Investors with Dramatic Improvement in Financial Performance and Enhanced Operational Efficiency

As an avid investor and keen observer of the financial markets, it is essential for me to analyze and interpret the latest financial results of prominent companies. In this article, we will dissect the recent financial performance of Kodiak Sciences Inc (KOD) during the April to June 30, 2023 reporting period and shed light on the company's prospects moving forward.
Firstly, it is important to address shareholders' expectations. Despite concerns that the company's top-line may remain stagnant, there has been a notable improvement in Kodiak Sciences Inc's operating shortfall. During the aforementioned period, the operating shortfall decreased to $-84.832 million from $-92.068 million in the same timeframe the previous year. This signifies that the company has enhanced its operational efficiency, which is encouraging news for stakeholders.

Kodiak Sciences Inc

Kodiak Sciences Inc Surprises Stock Market with Impressive Q1 2023 Results Despite Operating Loss

Kodiak Sciences Inc Reports Encouraging Results for Q1 2023
Investors in the biotechnology and pharmaceuticals sector should take note of a recent earnings report from Kodiak Sciences Inc. While the big players in the industry often get the most attention, there are some overlooked corporations that are well worth considering.
Kodiak recently announced that it has realized an operating loss of $-74.615 million for the first quarter of 2023. However, this is actually an improvement compared to the same period in the previous year, and the company's day-to-day operations have surpassed expectations.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com